Investigating how certain kinases affect glioblastoma treatment resistance
Official title: Evaluating the role of SPAK and OSR1 kinases in glioblastoma chemotherapy resistance
Funded at Mayo Clinic Jacksonville · NIH-10988456 · Data updated 2026-11-12
This study is looking at how two proteins, SPAK and OSR1, might help glioblastoma cells survive chemotherapy, with the hope of finding better treatments for patients battling this tough brain tumor.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Jacksonville NIH-funded |
| Lab location | 1 site (Jacksonville, United States) |
| Project start | July 8, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $402,401 |
| NIH project number | 1R21CA284153-01A1 |
| Project ID | NIH-10988456 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with glioblastoma who are undergoing or have undergone chemotherapy.
✕Less likely to help
Patients with other types of brain tumors or those who are not currently receiving treatment for glioblastoma may not benefit from this research.
What this research studies
This research focuses on glioblastoma, a highly aggressive brain tumor that is difficult to treat. The study aims to understand the roles of two specific kinases, SPAK and OSR1, which may help cancer cells resist chemotherapy by regulating cell volume and survival signals. By exploring how these kinases contribute to treatment resistance, the research seeks to identify new therapeutic strategies that could improve patient outcomes. Patients may benefit from insights that could lead to more effective treatments for glioblastoma.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that enhance the effectiveness of chemotherapy for glioblastoma patients.
How similar studies have gone: Previous research has shown that targeting similar pathways in cancer treatment can lead to improved outcomes, suggesting potential success for this approach.
Where this research is happening
-
Mayo Clinic Jacksonville
Jacksonville, United States Active
Researchers
- Principal investigator: Schiapparelli, Paula V — Mayo Clinic Jacksonville
- Study coordinator: Schiapparelli, Paula V
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.